A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia

Autor: Baltazar Gomez-Mancilla, Jean-Christophe Corvol, Gurutz Linazasoro, Izabela Rozenberg, Karla Eggert, Alberto J. Espay, Daniela Berg, Christian Geny, Pascal Derkinderen, Judit Sovago, Johannes Schwarz, Fabrizio Stocchi, Franck Durif, Andrew Feigin, Dominik Feuerbach, Jean-Luc Houeto, Thérèse Di Paolo, Claudia Trenkwalder, Judith Jaeger, Andres O. Ceballos-Baumann, Lin Zhang, Paul Maruff, Markus Weiss, Christine Tranchant, Donald Johns, Alexander Storch, Emmanuel Broussolle, Annamaria Jakab, Hans Ulrich Hockey, Olivier Rascol, Jean-Philippe Azulay, Luc Defebvre, Michal Gostkowski
Rok vydání: 2016
Předmět:
Zdroj: Movement Disorders. 31:1049-1054
ISSN: 0885-3185
DOI: 10.1002/mds.26569
Popis: Background This phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson's disease and levodopa-induced dyskinesia. Methods Patients with idiopathic Parkinson's disease and moderate to severe levodopa-induced dyskinesia were randomized to AQW051 10 mg (n = 24), AQW051 50 mg (n = 24), or placebo (n = 23) once daily for 28 days. Coprimary end points were change in Modified Abnormal Involuntary Movement Scale and Unified Parkinson's Disease Rating Scale part III scores. Secondary outcomes included pharmacokinetics. Results In total, 67 patients completed the study. AQW051-treated patients experienced no significant improvements in Modified Abnormal Involuntary Movement Scale or Unified Parkinson's Disease Rating Scale part III scores by day 28. AQW051 was well tolerated; the most common adverse events were dyskinesia, fatigue, nausea, and falls. Conclusions AQW051 did not significantly reduce dyskinesia or parkinsonian severity. © 2016 International Parkinson and Movement Disorder Society
Databáze: OpenAIRE
Externí odkaz: